Which pharmacotherapy has the strongest evidence for helping adults quit smoking?

Which pharmacotherapy has the strongest evidence for helping adults quit smoking?

• A. Varenicline
• B. Nicotine replacement therapy (patch, gum, lozenge, or inhaler)
• C. Bupropion
• D. Clonidine

Answer: (A)

The main idea here is which medication has the strongest, most consistent evidence that it helps adults stop smoking. Varenicline stands out because it works in two helpful ways: it’s a partial agonist at the alpha4beta2 nicotinic receptor, which reduces withdrawal symptoms, and it also blocks nicotine’s reward, making smoking less rewarding if you lapse. In many randomized trials, varenicline produces higher quit rates than placebo and tends to beat other common options like nicotine replacement therapy and bupropion, with effects seen at the end of treatment and during follow-up. Because of this abundant, replicated evidence, it’s widely considered a top first-line choice for adults aiming to quit. It’s typically started about a week before the quit date to allow gradual dose increases, which helps with tolerability. Common side effects include nausea and sleep-related issues such as vivid dreams, but serious problems are relatively uncommon for most people. In contrast, nicotine replacement therapy is effective and widely used, but head-to-head trials often show lower abstinence rates than varenicline; bupropion is also helpful but generally with a smaller effect; clonidine has the weakest supporting evidence for smoking cessation among these options.

The main idea here is which medication has the strongest, most consistent evidence that it helps adults stop smoking. Varenicline stands out because it works in two helpful ways: it’s a partial agonist at the alpha4beta2 nicotinic receptor, which reduces withdrawal symptoms, and it also blocks nicotine’s reward, making smoking less rewarding if you lapse. In many randomized trials, varenicline produces higher quit rates than placebo and tends to beat other common options like nicotine replacement therapy and bupropion, with effects seen at the end of treatment and during follow-up. Because of this abundant, replicated evidence, it’s widely considered a top first-line choice for adults aiming to quit. It’s typically started about a week before the quit date to allow gradual dose increases, which helps with tolerability. Common side effects include nausea and sleep-related issues such as vivid dreams, but serious problems are relatively uncommon for most people. In contrast, nicotine replacement therapy is effective and widely used, but head-to-head trials often show lower abstinence rates than varenicline; bupropion is also helpful but generally with a smaller effect; clonidine has the weakest supporting evidence for smoking cessation among these options.